SCT Plus Immune Therapy in Average Risk AML/MDS | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02117297

SCT Plus Immune Therapy in Average Risk AML/MDS
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Allogeneic stem cell transplantation followed by targeted immune therapy with Gemtuzumab Ozogamicin (Mylotarg) will be given to patients with average risk AML or MDS.

Status: 
Recruiting
Study Date: 
Wed, 11/02/2011 to Fri, 12/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Gemtuzumab Ozogamicin Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation. Other Name: Mylotarg